• Direct: latest news from coronavirus
  • Infographic: how the pandemic moved
  • Progress: Chinese Army Approves Coronavirus Vaccine for Military Use

Gilead Science has set a single price for remdesivir in developed countries at $ 390 (about 347 euros) per dose. The vast majority of patients are expected to receive a five-day treatment using 6 vials, equivalent to $ 2,340 for each person who needs it (approximately 2,079 euros).

In addition, Gilead reports that exceptionally in the case of the US, and due to the peculiarities of its health system, the price for private insurance companies will be 520 per vial (462 euros).

In this sense, the company highlights the cost-benefit of remdesivir from the first results of the Niaid study in hospitalized patients with Covid-19, which showed that the drug shortened recovery time by an average of four days .

Taking the example of the United States, an earlier discharge from hospital would result in a hospital savings of approximately $ 12,000 per patient (about 10,670 euros). Thus, Gilead emphasizes that considering these immediate savings for the health system, "the potential value that remdesivir provides is appreciated."

According to Daniel O'Day, President and CEO of Gilead Science, in an open letter published today, the unique situation caused by the coronavirus pandemic has required "a unique and exceptional solution to ensure that remdesivir is affordable and accessible to patients from all the world". In addition, the company believes that the fact that the price is much lower than expected by health systems and the general value that remdesivir provides will allow simplifying government negotiations to offer rapid and wide access to patients who need it.

In his letter, the CEO of Gilead points out that "there is no compendium on how to price a new medicine in a pandemic" and that they are aware "of the great responsibility that comes from putting a price on remdesivir and the need to be transparent in our decision".

O'Day also explains that in developing countries, "where health resources, infrastructure, and the economy are so different, we have entered into agreements with generic manufacturers to offer treatments at a substantially lower cost. These alternative solutions are designed to ensure that all countries in the world can provide access to treatment. "

Donation

In recent months, the company has donated all of its existing supply of remdesivir , totaling 1.5 million vials, to facilitate rapid access and enable clinical trials. In this post-donation phase, the company remains focused on facilitating quick access to remdesivir.

The company estimates investment in the development and manufacturing of remdesivir throughout this year at more than 1,000 million dollars (888 million euros) and has expressed its commitment to continue investigating its potential to help this pandemic in various ways. such as evaluating treatment earlier in the course of the disease, in outpatient settings, with an inhaled formulation, in additional patient groups and in combination with other therapies, as well as increasing supplies to meet the high world demand.

O'Day indicates in his open letter that his work is not yet done and cites among his longer term responsibilities: "Continue our ongoing work on remdesivir, maintain our long-term research on antivirals, and invest in scientific innovation that can help to future generations. "

According to the criteria of The Trust Project

Know more

  • Science and health
  • Coronavirus
  • Covid 19
  • Infectious diseases
  • Respiratory diseases
  • Descaled
  • New normal

Interview "Visual control against coronavirus in airports is useless, it is not endorsed by Europe"

The drug that could prevent the worst damages of Covid seen in autopsies

HealthAbandonment to the elderly, evidence of a weak social health system

See links of interest

  • News
  • Translator
  • Programming
  • Calendar
  • Horoscope
  • Classification
  • League calendar
  • Films
  • Cut notes
  • Themes
  • Multiple sclerosis
  • Granada CF - Eibar
  • Napoli - SPAL
  • Sampdoria - Bologna
  • Sassuolo - Verona
  • Espanyol - Real Madrid